MARKET

SRNEQ

SRNEQ

Sorrento Therapeutics Inc
OTCPK
0.341
+0.001
+0.35%
Opening 15:52 03/24 EDT
OPEN
0.320
PREV CLOSE
0.340
HIGH
0.357
LOW
0.320
VOLUME
879.42K
TURNOVER
296.51K
52 WEEK HIGH
3.090
52 WEEK LOW
0.161
MARKET CAP
161.01M
P/E (TTM)
-0.2566
1D
5D
1M
3M
1Y
5Y
Court Confirms Sorrento Therapeutics, Inc.'s $125 Million Arbitration Award Against NantPharma, LLC
Yahoo · 03/17 14:25
Scilex Holding Company And CH Trading Group Announce Territory Distribution Agreement To Expand Commercialization Of ZTlido For The Middle East And North Africa With $105M Minimum Multi-Year Purchase Commitment
Benzinga · 03/08 15:14
Is a Surprise Coming for Sorrento Therapeutics (SRNEQ) This Earnings Season?
NASDAQ · 03/02 15:57
Scilex Holding Company Announces The Commercial Launch Of ELYXYBTM In The U.S., Strengthening Its Leadership Position In Non-Opioid Pain Management
Benzinga · 02/27 14:09
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 02/22 21:31
Why Sorrento Therapeutics Stock Crashed Today
NASDAQ · 02/22 20:52
Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga · 02/22 18:10
Gilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment
Benzinga · 02/22 14:37
More
About SRNEQ
Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The Company is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.

Webull offers kinds of Sorrento Therapeutics Inc stock information, including OTCPK:SRNEQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNEQ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRNEQ stock methods without spending real money on the virtual paper trading platform.